Stockscreener 앱 받기
3.87
2.65%
0.10
시간 외 거래:
3.90
0.03
+0.78%
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
Zacks Research Issues Optimistic Forecast for IOVA Earnings - MarketBeat
IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) latest press releases and corporate news - Yahoo Finance Singapore
Long Focus Capital Management LLC Reduces Stock Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Gains Traction As Nasdaq Futures Reflect Biotech - Kalkine Media
Invenomic Capital Management LP Buys 2,246,945 Shares of Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Presents Five-Year Amtagvi Data at ASCO for Advanced Melanoma - MSN
IOVA Stock Quote Price and Forecast - CNN
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com
Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas - Yahoo Finance
Iovance Biotherapeutics Takes Steps Amidst Market Dynamics - timothysykes.com
What's going on with Iovance Biotherapeutics stock on Friday? - MSN
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments - MarketBeat
Iovance Biotherapeutics’ Latest Moves Shape Market Outlook - StocksToTrade
Iovance Biotherapeutics Faces Challenging Market Dynamics Amidst Financial Strain - timothysykes.com
Iovance Biotherapeutics Inc (IOVA) Stock Price, Trades & News - GuruFocus
IOVANCE (NASDAQ: IOVA) CFO awarded 132,200 RSUs in equity grant - Stock Titan
235,000 RSUs granted to Iovance (NASDAQ: IOVA) interim CEO Frederick Vogt - Stock Titan
Equity grant: IOVANCE (NASDAQ: IOVA) awards 117,500 RSUs to Chief Regulatory Officer - Stock Titan
Iovance (NASDAQ: IOVA) CMO awarded 58,750 RSUs as equity compensation - Stock Titan
Iovance (NASDAQ: IOVA) COO awarded 117,500 RSUs over 3 years - Stock Titan
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.5%What's Next? - MarketBeat
Iovance Biotherapeutics at Barclays Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
A Look At Iovance Biotherapeutics (IOVA) Valuation After Sharp Recent Share Price Momentum - Sahm
Iovance Biotherapeutics (IOVA) Is Up 42.7% After Positive Lifileucel Sarcoma Data And New Trial Plan - Sahm
Iovance Biotherapeutics stock hits 52-week high at 4.35 USD - Investing.com Nigeria
Iovance Biotherapeutics Shines with TIL Therapy Success and Financial Gain - timothysykes.com
Iovance Sarcoma Trial Data Puts TIL Platform And Stock In Focus - Yahoo Finance
Rhenman & Partners Asset Management AB Has $2.38 Million Stock Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance (IOVA) Soars 33%, Hits All-Time High - Insider Monkey
Iovance (IOVA) Hits 52-Week High as Analyst Doubles Price Target - Finviz
Iovance (IOVA) hits 52-week high as analyst doubles price target - MSN
Momentum Shift: Is Iovance Biotherapeutics Inc. stock a bargain at current levelsJuly 2025 Breakouts & Free Real-Time Market Sentiment Alerts - Naître et grandir
Iovance Biotherapeutics (IOVA) Stock Rallies on Analyst Upgrades, Amtagvi Momentum - International Business Times Australia
Iovance (NASDAQ: IOVA) CMO reports RSU vesting and tax share withholding - Stock Titan
Iovance (NASDAQ: IOVA) CRO reports RSU vesting and tax-share withholding - Stock Titan
Iovance (NASDAQ: IOVA) COO Bilinsky logs 31,246 RSUs vested and tax withholding shares - Stock Titan
Iovance Biotherapeutics jumps as analysts lift targets and short interest fuels momentum - Quiver Quantitative
Iovance Biotherapeutics Expands Clinical Trials Amid Strategic Upgrades - timothysykes.com
What's Going On With Iovance Biotherapeutics Stock On Friday? - Benzinga
Iovance Biotherapeutics Shines with Positive Trial Outcomes and Upgraded Ratings - StocksToTrade
UBS Raises PT on Iovance Biotherapeutics (IOVA) - Insider Monkey
Iovance Biotherapeutics stock hits 52-week high at 4.35 USD By Investing.com - Investing.com Canada
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - The Motley Fool
Key facts: Iovance Biotherapeutics expands TIL therapy; UBS raises price target - TradingView
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Raised to $4.00 at UBS Group - MarketBeat
UBS Adjusts Iovance Biotherapeutics Price Target to $4 From $2, Maintains Neutral Rating - marketscreener.com
RSU vesting boosts Iovance (NASDAQ: IOVA) CRO share holdings - Stock Titan
Iovance Biotherapeutics (NASDAQ:IOVA) Trading 9.9% Higher After Analyst Upgrade - MarketBeat
Iovance Biotherapeutics’ TIL Therapy Showcases Promising Results - StocksToTrade
Iovance Biotherapeutics: Short-Term Pain, Long-Term GainI'm Still Bullish After All These Years - Seeking Alpha
Iovance Biotherapeutics’ Stock Rallies After Promising Trial Data - timothysykes.com
Iovance (NASDAQ: IOVA) CMO reports RSU vesting and share tax withholding - Stock Titan
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Citizens Upgrades Iovance Biotherapeutics (IOVA) - Nasdaq
Assessing Iovance Biotherapeutics (IOVA) Valuation After Amtagvi Momentum And New Fast Track Designation - Sahm
IOVA Receives Analyst Upgrade to Market Outperform by Citizens | - GuruFocus
1.20%
0.06%
자본화:
|
볼륨(24시간):